Black Diamond Therapeutics develops cancer drugs that target families of related gene mutations in patients with tumors. BDTX reports earnings on Thu, Nov 5, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 29 | HC Wainwright & Co. | Reiterated | Buy | |
| Oct 16 | Stifel | Reinstated | Buy | |
| Jul 1 | Raymond James | Reinstated | Buy |
Seasonality
How BDTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in BDTX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BDTX is in one of them and how their past BDTX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered BDTX in an article yet. Here's the latest on the wider market.
About Black Diamond Therapeutics
Black Diamond Therapeutics is a drug developer based in Cambridge, Massachusetts. It develops cancer medicines designed to block families of related gene mutations rather than a single mutation, aiming to treat patients whose tumors have limited treatment options. Its lead candidate, silevertinib, is being tested in patients with lung cancer and brain tumors. The company has also licensed another candidate to Servier, which is developing it for cancer and genetic diseases.
- Headquarters
- Cambridge, MA